All Articles tagged Pombiliti®/Opfolda® (cipaglucosidase alfa + miglustat)

• Genetic Disorders
  September 18, 2024 EDT
  Health-Related Quality-of-Life Utility Values in Adults With Late-Onset Pompe Disease: Analyses of EQ-5D Data From the PROPEL Clinical Trial
  Alison GriffithsSimon ShohetNeil JohnsonAlasdair MacCulloch

  This analysis of EQ-5D health-related quality-of-life utility data from the PROPEL clinical trial compared cipaglucosidase alfa plus miglustat vs alglucosidase alfa plus placebo in late-onset Pompe disease.

  Abstract